Terragen raises $7M to cccelerate biotech expansion

Australian biotech firm Terragen (ASX:TGH) announced binding commitments for a $7 million equity raising.

The capital injection, achieved through the issuance of new fully paid ordinary shares at $0.022 each, marks a pivotal moment for the company as it seeks to validate its product range.

The funding structure is bifurcated into two distinct tranches. The first involves an institutional placement of approximately $2.8 million utilising the company’s existing placement capacity.

The second, a conditional placement of $4.2 million, is subject to shareholder approval.

Non-executive Director Scobie Ward has demonstrated strong internal confidence by committing $2.3 million to the raising.

The capital boost significantly enhances Terragen's financial standing, bringing its pro forma cash position to approximately $9.8 million as of late 2025.

The proceeds are earmarked for high-impact initiatives: advancing research and development to diversify their biological product offerings and scaling their commercial footprint internationally.